Maglasang, Judelyn S.
HRN: 15-02-81 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/14/2024
CO-AMOXICLAV 625MG (TAB)
03/14/2024
03/20/2024
PO
625mg
BID
S/P RMLE
Waiting Final Action
Indication: Prophylaxis Type of Infection: Prophylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes